{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:26:59Z","timestamp":1754598419110},"reference-count":24,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1778,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1111\/j.1365-2710.2010.01179.x","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T06:12:31Z","timestamp":1287468751000},"page":"237-245","source":"Crossref","is-referenced-by-count":12,"title":["Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value\u00a0?"],"prefix":"10.1155","volume":"36","author":[{"given":"N.","family":"Martelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Margueritte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Bozonnat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Daur\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bressolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hillaire-Buys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2010,10,19]]},"reference":[{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.23169","article-title":"Trends in childhood cancer incidence in the U.S. (1992-2004)","volume":"112","author":"Linabery","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejca.2005.08.041","article-title":"Survival in France after childhood acute leukaemia and non-Hodgkin\u2019s lymphoma (1990-2000)","volume":"42","author":"Goubin","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB3|cit3","first-page":"456","article-title":"High-dose methotrexate and\/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?","volume":"52","author":"Sterba","year":"2005","journal-title":"Neoplasma"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00262416","article-title":"Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients","volume":"3","author":"Evans","year":"1979","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB5|cit5","first-page":"81","article-title":"Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia","volume":"5","author":"Evans","year":"1987","journal-title":"NCI Monographs"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1002\/1097-0142(19871215)60:12<3020::AID-CNCR2820601227>3.0.CO;2-0","article-title":"Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children","volume":"60","author":"Borsi","year":"1987","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0145-2126(96)00127-0","article-title":"On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia","volume":"21","author":"Seidel","year":"1997","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB9|cit9","first-page":"2257","article-title":"Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report","volume":"14","author":"Vilmer","year":"2000","journal-title":"Children Leukemia Cooperative Group. Leukemia"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB10|cit10","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-006-0394-3","article-title":"A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia","volume":"60","author":"Piard","year":"2007","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1472-8206.1999.tb00366.x","article-title":"Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach","volume":"13","author":"Odoul","year":"1999","journal-title":"Fundamental and Clinical Pharmacologyundam"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mpo.2950240303","article-title":"Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia","volume":"24","author":"Donelli","year":"1995","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF00315414","article-title":"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue","volume":"39","author":"Wolfrom","year":"1990","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008469-200404000-00002","article-title":"Incidence of childhood leukaemia and non-Hodgkin\u2019s lymphoma in France: National Registry of Childhood Leukaemia and Lymphoma, 1990-1999","volume":"13","author":"Clavel","year":"2004","journal-title":"European Journal of Cancer Prevention"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1999.17.3.818","article-title":"Sex differences in prognosis for children with acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/14622416.8.7.817","article-title":"Pharmacogenomics of acute leukemia","volume":"8","author":"Ansari","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/1078-0432.CCR-06-2145","article-title":"Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"13","author":"Ge","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","article-title":"Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia","volume":"100","author":"Laverdiere","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB23|cit23","first-page":"1113","article-title":"Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia","volume":"91","author":"Costea","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2010.01179.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mpo.1149","article-title":"Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline","volume":"36","author":"Peyriere","year":"2001","journal-title":"Medical and Pediatric Oncology"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2010.01179.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2010.01179.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T21:42:00Z","timestamp":1685828520000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2010.01179.x"}},"subtitle":["Methotrexate pharmacokinetics in childhood ALL"],"short-title":[],"issued":{"date-parts":[[2010,10,19]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01179.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10,19]]}}}